Home > Neurology > MS Virtual 2020 > Treatment Strategies and Results > Safety and efficacy of cladribine, glatiramer acetate, and more

Safety and efficacy of cladribine, glatiramer acetate, and more


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
Trial
CLASSIC-MS, OPTIMUM
Interim data on long-term efficacy and durability of effect of cladribine tablets from CLASSIC-MS, with a median of 10 years follow-up, were presented [1]. Interim results of 147 participants of this phase 4 study suggested sustained efficacy of cladribine following 2 annual treatment cycles, with a substantial proportion of patients requiring no further treatment with a disease-modifying treatment or assistive ambulatory device. Median time since last parent study dose (LPSD) was 10 (range 8-14) years. Of 147 patients, 139 (94.6%) did not use a wheelchair/were not bedridden in the 3 months prior to CLASSIC-MS; 123 (83.7%) did not need an ambulatory device (EDSS <6) at any time since LPSD. The majority of patients (93/147: 63.3%) received no subsequent DMT after LPSD, and 59.1% maintained active employment. The safety, tolerability, and efficacy in te...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on